NTM Infection Market Set to Surge by 2034 — DelveInsight Report The Nontuberculous Mycobacterial (NTM) infection market is expected to witness significant growth by 2034, driven by rising prevalence, increased awareness, and the introduction of promising pipeline therapies. 🔬 Market Highlights The market is projected to grow at a notable CAGR (2020–2034) across the US, EU5, and Japan. The U.S. market was valued at $360 million in 2023, with ARIKAYCE (Insmed) generating $223 million. Macrolide drugs, ethambutol, and rifampin also contributed substantially to the treatment landscape. Off-label therapies contributed roughly $41 million in 2023. 👉 Explore the full DelveInsight NTM Infection Market Report 🧫 Epidemiology Insights In the U.S., 108,000 NTM cases were diagnosed in 2023, with 68% female patients. Most common pathogens: Mycobacterium avium – 76,000 cases M. abscessus – 14,000 cases M. kansasii and M. xenopi – 18,000 cases combined Pulmonary infections dominated with 86,000 cases vs. 22,000 extrapulmonary cases. 💊 Key Pipeline Therapies MRX-5 (MicuRx): Received FDA Orphan Drug Designation in Dec 2024. SPR719 (Spero Therapeutics): Showed positive Phase 1 data in Oct 2024. Noteworthy therapies: ARIKAYCE, MNKD-101, SPR720, Molgradex, NUZYRA, Thiolanox, CYT 107, RHB-204 🧪 Learn about emerging treatments and drug uptake trends 🔍 Market Drivers & Challenges Drivers: Investment in branded therapies Ongoing clinical trials for new treatments Challenges: Diagnosis difficulties Lack of disease awareness Limited biomarkers for clinical trials 🧠 Leading Companies in the NTM Space Insmed AN2 Therapeutics MannKind Corporation Spero Therapeutics Savara Pharmaceuticals Mallinckrodt Paratek Pharmaceuticals RevImmune 📥 Download a Free Sample Report https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-market?utm_source=report&utm_medium=promotion&utm_campaign=hpr